About Hibiskus
Hibiskus is a Healthcare company based in Kalamazoo (United States) founded in 2017 by Andre Bachmann and Michael Pirrung, and was acquired by Lodo Therapeutics in September 2020. Small-molecule therapeutics for cancer are developed by Hibiskus. The company was acqui-hired. Its focus areas include Life Sciences, Immunotherapy, Small Molecule and Innate Immune System. Its competitors include Revolution Medicines, Blueprint Medicines and Syndax; 3 of its 3 listed competitors have raised funding.
Company details
Hibiskus Biopharma is a developer of small-molecule therapeutic solutions for cancer treatment. It has developed TIR-199 drugs that work as a potent proteasome inhibitor from the syrbactin natural product family. The product contains a proteasome inhibitor that helps to induce cell death of tumor cell types. It inhibits the digestive function of proteasomes which induces a cytotoxic buildup of cellular proteins that activates apoptotic pathways. It has developed FDA-approved drugs, target multiple myeloma, antibodies that produce cells in the blood others. Features include high-potency against proteasome activity cellular proliferation indicating a superior safety profile, induces cell death, and others.
- Headquarters Kalamazoo, United States
- Founders Andre Bachmann, Michael Pirrung
- Stage Acquired
- SectorsHealthcare
- Website hibiskusbio.com
- Acquired by Lodo Therapeutics (Sep 2020)
- Investors
- Acquired byLodo Therapeutics
(Sep 2020)
Investors in Hibiskus
Hibiskus has secured backing from 1 investor. Prominent investors backing the company include Lodo Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer novel therapeutics to treat resistant infectious diseases and cancers using AI | 2015 | lodotherapeutics.com | New York, United States |
Investor details for Hibiskus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Hibiskus
2 people are tracked at Hibiskus (2 in leadership).
| Name | Role | Group |
|---|---|---|
Andre Bachmann | Co-Founder | Leadership |
Michael Pirrung | Co-Founder | Leadership |
Complete people profiles for Hibiskus
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Hibiskus
2 dated milestones of Hibiskus across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Hibiskus is founded.
- Exit Acquired by Lodo Therapeutics.
Competitors of Hibiskus
Hibiskus has 3 listed competitors in our database, 3 of them funded. They include Revolution Medicines, Blueprint Medicines and Syndax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. |
Detailed competitors of Hibiskus
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Hibiskus (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hibiskus
Complete news archive for Hibiskus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hibiskus
Hibiskus was founded in 2017.
Hibiskus is headquartered in Kalamazoo, United States. It is registered at Kalamazoo, Michigan, United States.
Hibiskus Biopharma is a developer of small-molecule therapeutic solutions for cancer treatment. It has developed TIR-199 drugs that work as a potent proteasome inhibitor from the syrbactin natural product family. The product contains a proteasome inhibitor that helps to induce cell death of tumor cell types. It inhibits the digestive function of proteasomes which induces a cytotoxic buildup of cellular proteins that activates apoptotic pathways. It has developed FDA-approved drugs, target multiple myeloma, antibodies that produce cells in the blood others. Features include high-potency against proteasome activity cellular proliferation indicating a superior safety profile, induces cell death, and others.
Hibiskus's top competitors include Syndax, Revolution Medicines and Blueprint Medicines.
Hibiskus has 1 investor. Key investors include Lodo Therapeutics.
Yes. Hibiskus was acquired by Lodo Therapeutics in September 2020.

